<DOC>
	<DOCNO>NCT00912444</DOCNO>
	<brief_summary>The purpose study compare pathological complete response ( pCR ) rate triple-negative Her2 positive breast cancer patient treat neoadjuvant docetaxel , anthracycline cyclophosphamide ( TAC ) docetaxel cyclophosphamide ( TC ) regimen .</brief_summary>
	<brief_title>Neoadjuvant Treatment Docetaxel , Anthracycline Cyclophosphamide ( TAC ) Versus Docetaxel Cyclophosphamide ( TC ) Triple-Negative Her2 Positive Breast Cancer</brief_title>
	<detailed_description>Breast cancer lead cause cancer woman China . Neoadjuvant chemotherapy treatment locally advance breast cancer become standard therapy . Results neoadjuvant trial show pathological complete response ( pCR ) independent predictor outcome . Docetaxel introduce clinical practice early 1990s demonstrate good activity adjuvant metastatic setting . Both TC TAC effective regimen adjuvant setting . The optimal regimen neoadjuvant treatment however unknown . This especially true triple-negative HER2 positive breast cancer . This study evaluate pCR rate TAC TC neoadjuvant treatment triple-negative HER2 positive breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Women age ≥ 18 year &lt; 70 year Karnofsky performance status ( KPS ) ≥ 70 At least one measurable disease accord RECIST . histologically confirm invasive breast cancer ( exclude inflammatory breast cancer ) , T2N1 locally advance breast cancer ( T34N03 T04N23 ) Biopsy specimens available ER , PgR Her2 detection , patient triple negative Her2 positive breast cancer , Her2 positivity define FISH/CISH Her2 positive IHC Her2 3+ , Triplenegative disease define negativity ER , PgR Her2 Adequate bone marrow function : Neutrophil ≥ 1.5*109/L ; Hb ≥ 100g/L ; PLT ≥ 100*109/L An estimate life expectancy least 12 month Willing take biopsy neoadjuvant chemotherapy patient must accessible treatment followup Women potential childbearing must negative pregnancy test ( urine serum ) within 7 day drug administration agree use acceptable method birth control avoid pregnancy duration study Written inform consent accord GCP Prior systemic locoregional treatment breast cancer , include chemotherapy Metastatic breast cancer With history malignant tumor except uterine cervix cancer situ skin basal cell carcinoma Patients medical condition indicate intolerant neoadjuvant therapy relate treatment , include uncontrolled pulmonary disease , diabetes mellitis , severe infection , active peptic ulcer , coagulation disorder , connective tissue disease myelosuppressive disease inadequate liver function ( bilirubin &gt; 1.0 time upper normal limit [ UNL ] ALT and/or AST &gt; 1.5 UNL associate alkaline phosphatase &gt; 2.5 UNL ; inadequate renal function ( creatinine &gt; 1.0 time UNL case limit value , Creatinine clearance &lt; 60 ml/min ) Contraindication use dexamethasone History congestive heart failure , uncontrolled symptomatic angina pectoris , arrhythmia myocardial infarction ; poorly control hypertension ( systolic BP &gt; 180 mmHg diastolic BP &gt; 100 mmHg ) Has peripheral neuropathy ≥ grade 1 Patient pregnant breast feed Known severe hypersensitivity drug study Treatment investigational drug within 30 day begin study treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Breast Neoplasms</keyword>
	<keyword>Neoadjuvant</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Anthracycline</keyword>
</DOC>